ASMB Assembly Biosciences, Inc. gains 17% Mar 5, 2018

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. http://www.priceseries.com/trade/ASMB-Assembly-Biosciences-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2018021320180305.html